-

10:46:35 PM

GTHX Stock News

GTHX - G1 Therapeutics Inc

09/05/23 11:00 AM

Nasdaq : GTHX

conferences

G1 Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1’s Communications Officer Will Roberts will provide a corporate presentation on September 12, 2023, at 9:30 AM EDT during the H.C.

RHEA-AI

neutral

09/01/23 4:15 PM

Nasdaq : GTHX

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 6,800 shares of G1’s common stock and 3,300 restricted stock units (RSUs) to two hired

RHEA-AI

very positive

08/02/23 6:30 AM

Nasdaq : GTHX

earnings

G1 Therapeutics Provides Second Quarter 2023 Financial Results and Operational Highlights

- Recognized Total Revenue of $42.4 Million, Including $11.1 Million in Net COSELA® (trilaciclib) Revenue - - Reiterated Expectation for Interim Overall Survival (OS) Analysis of Pivotal Phase 3 Trial in Metastatic Triple Negative Breast Cancer (TNBC) in the First Quarter of 2024 - - Presented New

RHEA-AI

neutral

07/31/23 2:30 PM

Nasdaq : GTHX

conferences

G1 Therapeutics to Participate in Two August Investor Conferences

G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that it will participate in two August investor conferences. On Monday August 7, 2023, G1’s Chief Executive Officer Jack Bailey and other

RHEA-AI

neutral

07/31/23 8:30 AM

Nasdaq : GTHX

New Publication Highlights Real World Impact of Trilaciclib on Myelosuppressive Events in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC)

- Results Confirm that Trilaciclib Reduces Single and Multilineage Grade ≥3 Myelosuppressive Hematologic Adverse Events (HAEs) Including Neutropenia, Anemia, and Thrombocytopenia - - Analyses Showed Consistently Lower Cytopenia-Related Healthcare Utilization and All-Cause Hospitalization Among

RHEA-AI

neutral

07/26/23 9:00 AM

Nasdaq : GTHX

earnings

G1 Therapeutics to Release Second Quarter 2023 Financial Results and Provide Business Update on August 2, 2023

G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a financial and corporate update for the second quarter 2023 on Wednesday August 2, 2023, at 8:30 a.m. ET.

RHEA-AI

neutral

07/06/23 4:15 PM

Nasdaq : GTHX

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 5,600 shares of G1’s common stock and 2,800 restricted stock units (RSUs) to two hired

RHEA-AI

very positive

06/04/23 7:13 AM

Nasdaq : GTHX

Trilaciclib Increases Pool of Memory T Cells in the Tumor Microenvironment Responsible for Long Term Immune Surveillance and Efficacy

- Phase 2 Mechanism of Action Trial Results Demonstrate the Immunomodulatory Effects of Trilaciclib in the Tumor Microenvironment - - Trilaciclib Enhances Expression of Genes Associated with Memory T Cells - - Trilaciclib Increases Multiple Surrogate Immune Markers for Memory CD8+ T Cell

RHEA-AI

positive

06/01/23 4:40 PM

Nasdaq : GTHX

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 6,300 shares of G1’s common stock and 3,000 restricted stock units (RSUs) to three hired

RHEA-AI

very positive

05/22/23 4:45 PM

Nasdaq : GTHX

management

G1 Therapeutics Announces Appointment of Monica Thomas as General Counsel

G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the appointment of Monica

RHEA-AI

very positive

1 2 3 4 5 6 7 8 9 10 Next